Literature DB >> 27561242

Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Lester J Layfield1, Sinchita Roy-Chowdhuri2, Zubair Baloch3, Hormoz Ehya4, Kim Geisinger5, Susan J Hsiao6, Oscar Lin7, Neal I Lindeman8, Michael Roh9, Fernando Schmitt10, Nikoletta Sidiropoulos11, Paul A VanderLaan12.   

Abstract

The Papanicolaou Society of Cytopathology has developed a set of guidelines for respiratory cytology including indications for sputum examination, bronchial washings and brushings, CT-guided FNA and endobronchial ultrasound guided fine needle aspiration (EBUS-FNA), as well as recommendations for classification and criteria, ancillary testing and post-cytologic diagnosis management and follow-up. All recommendation documents are based on the expertise of committee members, an extensive literature review, and feedback from presentations at national and international conferences. The guideline documents selectively present the results of these discussions. The present document summarizes recommendations for ancillary testing of cytologic samples. Ancillary testing including microbiologic, immunocytochemical, flow cytometric, and molecular testing, including next-generation sequencing are discussed. Diagn. Cytopathol. 2016;44:1000-1009.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cytology; flow cytometry; immunocytochemistry; molecular diagnostics; next-generation sequencing

Mesh:

Substances:

Year:  2016        PMID: 27561242      PMCID: PMC5590370          DOI: 10.1002/dc.23549

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  91 in total

1.  Expression and rearrangement of the ROS1 gene in human glioblastoma cells.

Authors:  C Birchmeier; S Sharma; M Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  Next-generation sequencing and the cytopathologist.

Authors:  Catherine I Dumur; Adele O Kraft
Journal:  Cancer Cytopathol       Date:  2014-12-29       Impact factor: 5.284

3.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

Review 4.  Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.

Authors:  Lorenza Landi; Gabriele Minuti; Armida D'Incecco; Federico Cappuzzo
Journal:  Curr Opin Oncol       Date:  2013-03       Impact factor: 3.645

5.  p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2.

Authors:  Takahiro Tatsumori; Koji Tsuta; Kyohei Masai; Tomoaki Kinno; Tomoko Taniyama; Akihiko Yoshida; Kenji Suzuki; Hitoshi Tsuda
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 May-Jun

6.  Subclassification of non-small cell lung cancer by cytologic sampling: a logical approach with selective use of immunocytochemistry.

Authors:  Hillary Z Kimbrell; Karen S Gustafson; Min Huang; Hormoz Ehya
Journal:  Acta Cytol       Date:  2012-07-25       Impact factor: 2.319

Review 7.  Personalized therapy on the horizon for squamous cell carcinoma of the lung.

Authors:  Han Sang Kim; Tetsuya Mitsudomi; Ross A Soo; Byoung Chul Cho
Journal:  Lung Cancer       Date:  2013-03-13       Impact factor: 5.705

8.  Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma.

Authors:  T Ueno; S Linder; G Elmberger
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

9.  Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.

Authors:  S Savic; C Tapia; B Grilli; A Rufle; M P Bihl; A de Vito Barascud; M Herzog; L Terracciano; F Baty; L Bubendorf
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

10.  Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?

Authors:  Debu Tripathy; Kathleen Harnden; Kimberly Blackwell; Mark Robson
Journal:  BMC Med       Date:  2014-08-12       Impact factor: 8.775

View more
  5 in total

1.  Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients.

Authors:  Simon R Turner; Darren Buonocore; Patrice Desmeules; Natasha Rekhtman; Snjezana Dogan; Oscar Lin; Maria E Arcila; David R Jones; James Huang
Journal:  Lung Cancer       Date:  2018-03-07       Impact factor: 5.705

2.  Current classification systems and standardized terminology in cytopathology.

Authors:  Tibor Mezei
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

3.  Crown-Cut Endobronchial Ultrasound Guided Transbronchial Aspiration Needle: First Real-World Experiences.

Authors:  Filiz Oezkan; Woo Yul Byun; Clemens Loeffler; Udo Siebolts; Linda Diessel; Nina Lambrecht; Stephan Eisenmann
Journal:  J Clin Med       Date:  2021-12-29       Impact factor: 4.241

4.  Conformity of Fine Needle Aspiration Biopsy (FNAB) and Core Needle Biopsy (CNB) in peripheral lung tumor patients: A cross-sectional study.

Authors:  Isnin Anang Marhana; Kadek Widianiti; Etty Hary Kusumastuti
Journal:  Ann Med Surg (Lond)       Date:  2022-03-05

Review 5.  Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review.

Authors:  Alessandro Caputo; Angela D'Ardia; Francesco Sabbatino; Caterina Picariello; Chiara Ciaparrone; Pio Zeppa; Antonio D'Antonio
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.